202 related articles for article (PubMed ID: 8091317)
1. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.
Nasser SM; Bell GS; Hawksworth RJ; Spruce KE; MacMillan R; Williams AJ; Lee TH; Arm JP
Thorax; 1994 Aug; 49(8):743-8. PubMed ID: 8091317
[TBL] [Abstract][Full Text] [Related]
2. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Nasser SM; Bell GS; Foster S; Spruce KE; MacMillan R; Williams AJ; Lee TH; Arm JP
Thorax; 1994 Aug; 49(8):749-56. PubMed ID: 8091318
[TBL] [Abstract][Full Text] [Related]
3. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
Diamant Z; Timmers MC; van der Veen H; Friedman BS; De Smet M; Depré M; Hilliard D; Bel EH; Sterk PJ
J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):42-51. PubMed ID: 7822663
[TBL] [Abstract][Full Text] [Related]
4. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Hui KP; Taylor IK; Taylor GW; Rubin P; Kesterson J; Barnes NC; Barnes PJ
Thorax; 1991 Mar; 46(3):184-9. PubMed ID: 1851340
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.
Hamilton AL; Watson RM; Wyile G; O'Byrne PM
Thorax; 1997 Apr; 52(4):348-54. PubMed ID: 9196518
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005.
Dahlén B; Kumlin M; Ihre E; Zetterström O; Dahlén SE
Thorax; 1997 Apr; 52(4):342-7. PubMed ID: 9196517
[TBL] [Abstract][Full Text] [Related]
7. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.
Diamant Z; Grootendorst DC; Veselic-Charvat M; Timmers MC; De Smet M; Leff JA; Seidenberg BC; Zwinderman AH; Peszek I; Sterk PJ
Clin Exp Allergy; 1999 Jan; 29(1):42-51. PubMed ID: 10051701
[TBL] [Abstract][Full Text] [Related]
8. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air.
Fischer AR; Rosenberg MA; Roth M; Loper M; Jungerwirth S; Israel E
Thorax; 1997 Dec; 52(12):1074-7. PubMed ID: 9516902
[TBL] [Abstract][Full Text] [Related]
9. Early increase in urinary leukotriene E4 (LTE4) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects.
Bancalari L; Conti I; Giannessi D; Lazzerini G; Dente FL; De Caterina R; Paggiaro PL
Allergy; 1999 Dec; 54(12):1278-85. PubMed ID: 10688431
[TBL] [Abstract][Full Text] [Related]
10. Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma.
Barchuk W; Lambert J; Fuhr R; Jiang JZ; Bertelsen K; Fourie A; Liu X; Silkoff PE; Barnathan ES; Thurmond R
Pulm Pharmacol Ther; 2014 Oct; 29(1):15-23. PubMed ID: 25018015
[TBL] [Abstract][Full Text] [Related]
11. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.
Van Schoor J; Joos GF; Kips JC; Drajesk JF; Carpentier PJ; Pauwels RA
Am J Respir Crit Care Med; 1997 Mar; 155(3):875-80. PubMed ID: 9117020
[TBL] [Abstract][Full Text] [Related]
12. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.
Friedman BS; Bel EH; Buntinx A; Tanaka W; Han YH; Shingo S; Spector R; Sterk P
Am Rev Respir Dis; 1993 Apr; 147(4):839-44. PubMed ID: 8385430
[TBL] [Abstract][Full Text] [Related]
13. The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys.
Turner CR; Smith WB; Andresen CJ; Eggler JF; Watson JW
Inflamm Res; 1996 Jan; 45(1):42-9. PubMed ID: 8821778
[TBL] [Abstract][Full Text] [Related]
14. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.
Lehnigk B; Rabe KF; Dent G; Herst RS; Carpentier PJ; Magnussen H
Eur Respir J; 1998 Mar; 11(3):617-23. PubMed ID: 9596112
[TBL] [Abstract][Full Text] [Related]
15. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.
Evans DJ; Barnes PJ; Spaethe SM; van Alstyne EL; Mitchell MI; O'Connor BJ
Thorax; 1996 Dec; 51(12):1178-84. PubMed ID: 8994512
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions.
O'Sullivan S; Roquet A; Dahlén B; Dahlén S; Kumlin M
Clin Exp Allergy; 1998 Nov; 28(11):1332-9. PubMed ID: 9824404
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporin A on the allergen-induced late asthmatic reaction.
Sihra BS; Kon OM; Durham SR; Walker S; Barnes NC; Kay AB
Thorax; 1997 May; 52(5):447-52. PubMed ID: 9176537
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
Wenzel SE; Trudeau JB; Kaminsky DA; Cohn J; Martin RJ; Westcott JY
Am J Respir Crit Care Med; 1995 Sep; 152(3):897-905. PubMed ID: 7663802
[TBL] [Abstract][Full Text] [Related]
19. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma.
Kent SE; Boyce M; Diamant Z; Singh D; O'Connor BJ; Saggu PS; Norris V
Clin Exp Allergy; 2013 Feb; 43(2):177-86. PubMed ID: 23331559
[TBL] [Abstract][Full Text] [Related]
20. The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses.
Kusner EJ; Buckner CK; Dea DM; DeHaas CJ; Marks RL; Krell RD
Eur J Pharmacol; 1994 May; 257(3):285-92. PubMed ID: 7522174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
